Last reviewed · How we verify

Infanrix-IPV/Hib

GlaxoSmithKline · FDA-approved active Biologic

Infanrix-IPV/Hib is a combination vaccine Biologic drug developed by GlaxoSmithKline. It is currently FDA-approved for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children. Also known as: DTPa-combined vaccine.

Infanrix-IPV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

Infanrix-IPV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameInfanrix-IPV/Hib
Also known asDTPa-combined vaccine
SponsorGlaxoSmithKline
Drug classcombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, inactivated poliovirus particles, and Haemophilus influenzae type b conjugate antigen. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory cells against these five pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Infanrix-IPV/Hib

What is Infanrix-IPV/Hib?

Infanrix-IPV/Hib is a combination vaccine drug developed by GlaxoSmithKline, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does Infanrix-IPV/Hib work?

Infanrix-IPV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is Infanrix-IPV/Hib used for?

Infanrix-IPV/Hib is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes Infanrix-IPV/Hib?

Infanrix-IPV/Hib is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Infanrix-IPV/Hib also known as anything else?

Infanrix-IPV/Hib is also known as DTPa-combined vaccine.

What drug class is Infanrix-IPV/Hib in?

Infanrix-IPV/Hib belongs to the combination vaccine class. See all combination vaccine drugs at /class/combination-vaccine.

What development phase is Infanrix-IPV/Hib in?

Infanrix-IPV/Hib is FDA-approved (marketed).

What are the side effects of Infanrix-IPV/Hib?

Common side effects of Infanrix-IPV/Hib include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing